Trial · NCT03818035
Participant flow104
How many started, completed or left each group, period by period.
1 to 20 of 104
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 1 Group 1: Guselkumab 100mg | 880 | |
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 2 Group 2a: Guselkumab 100 mg Q8W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 2 Group 2b: Guselkumab 100 mg Q16W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 2 Group 2c: Guselkumab 100 mg Q8W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 3 Group 3a: Withdrawal (Q8W) | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 3 Group 3b: Withdrawal (Q16W) | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | STARTED | Part 3 Group 3c: Re-Treatment Guselkumab 100mg | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 1 Group 1: Guselkumab 100mg | 822 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 2 Group 2a: Guselkumab 100 mg Q8W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 2 Group 2b: Guselkumab 100 mg Q16W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 2 Group 2c: Guselkumab 100 mg Q8W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 2 Group 2d: Re-Treatment Guselkumab 100mg | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 3 Group 3a: Withdrawal (Q8W) | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 3 Group 3b: Withdrawal (Q16W) | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | COMPLETED | Part 3 Group 3c: Re-Treatment Guselkumab 100mg | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | NOT COMPLETED | Part 1 Group 1: Guselkumab 100mg | 58 | |
| Part 1: Open-label (Week 0 to Week 8) | NOT COMPLETED | Part 2 Group 2a: Guselkumab 100 mg Q8W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | NOT COMPLETED | Part 2 Group 2b: Guselkumab 100 mg Q16W | 0 | |
| Part 1: Open-label (Week 0 to Week 8) | NOT COMPLETED | Part 2 Group 2c: Guselkumab 100 mg Q8W | 0 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03818035/flow